Pharmacovigilance quietly pays the most

Ask people in clinical research which function pays best and they will usually name biostatistics or statistical programming. The federal wage data says otherwise. When we processed the full H-1B disclosure file, the highest median wage among the clinical research functions did not belong to the quantitative roles. It belonged to pharmacovigilance, the drug-safety work that rarely gets mentioned in career advice at all.

The number

Certified H-1B filings for pharmacovigilance and drug safety roles, fiscal 2026 through Q2, posted a median of about $155,000, with the top 10 percent reaching about $225,000. Compare that to the quantitative functions that usually get the attention: biostatisticians at about $113,000, statistical programmers at about $132,000, statisticians at about $134,000. Pharmacovigilance sits above all of them at the median.

The sample is smaller than for the quantitative roles, so read the exact figure as directional. But the direction is clear and consistent: safety pays a premium, and it does so quietly.

Why safety pays

The premium makes sense once you look at what the work is. Pharmacovigilance is the function that monitors, assesses, and reports the safety of a drug, across trials and after approval. It is highly regulated, unforgiving of error, and directly tied to patient harm and regulatory risk. A mistake in a safety signal is not a data-cleaning inconvenience; it is a potential regulatory action or a harmed patient. That combination, deep regulatory expertise plus low tolerance for error plus real consequence, is exactly what commands scarcity pay. The filings also skew heavily toward the senior wage levels, with almost none at the entry tier, which tells you employers classify these as experienced roles by default.

Why nobody talks about it

Pharmacovigilance pays well and stays off the career-advice radar for the same reason: it is unglamorous. It does not have the quantitative mystique of biostatistics or the visible field role of monitoring. It is careful, regulated, document-heavy work that most people outside it underestimate. That gap between how well it pays and how little it is discussed is a small career arbitrage: a well-compensated, in-demand function that fewer people target precisely because it is quiet.

What the data cannot tell you

The filings show pharmacovigilance posting the highest median in the group, but the sample is modest and covers only visa-sponsored roles. They do not tell you what the function pays across the whole workforce, how it varies by employer, or what the day-to-day and the career path actually feel like. Those are the things someone weighing a move into safety would want to know, and they only exist with the people doing it. If you work in pharmacovigilance or drug safety, add your datapoint, and put a real, broad-based number on the best-kept pay secret in clinical research.